Urinary excretion of nitrate, nitrite and N-nitroso compounds in Schistosomiasis and bilharzia bladder cancer patients.
Urinary excretion of nitrate, nitrite and N-nitroso compounds in Schistosomiasis and bilharzia bladder cancer patients.
复制标题
血吸虫病和血吸虫膀胱癌患者尿液中硝酸盐、亚硝酸盐和 N-亚硝基化合物的排泄。
DOI：
10.1093/carcin/10.3.547
复制
发表时间：
1989
期刊：
影响因子：
4.7
通讯作者：
R. Preussmann
中科院分区：
文献类型：
--
作者：
A. Tricker;Mostafa H. Mostafa;Bertold Spiegelhalder;R. Preussmann
收集男性血吸虫病患者的唾液和24小时尿标本。血吸虫感染和可能并发的S.未诊断膀胱癌的曼氏血吸虫感染患者（n = 27）、诊断膀胱癌的血吸虫患者（n = 23）以及来自埃及尼罗河三角洲地区的无血吸虫感染和/或细菌性尿路感染的健康埃及志愿者的比较对照组（n = 27）。分析唾液样本中硝酸盐和亚硝酸盐的存在;分析尿液样本中硝酸盐、亚硝酸盐、挥发性和非挥发性N-亚硝基化合物的存在。诊断膀胱癌之前和之后的血吸虫病患者定期排出游离亚硝酸盐以及挥发性亚硝胺（N-亚硝基二甲胺、N-亚硝基二乙胺、N-亚硝基哌啶和N-亚硝基吡咯烷），此外还存在浓度升高的非挥发性N-亚硝胺酸（N-亚硝基脯氨酸、N-亚硝基肌氨酸、N-亚硝基噻唑烷-4-羧酸及其2-甲基衍生物）。在埃及对照组中观察到挥发性N-亚硝基化合物（0.32 +/- 0.64微克/天;平均值+/- SD）和非挥发性N-亚硝基化合物（31.20 +/- 22.07微克/天）的总尿排泄量。血吸虫病患者的血药浓度显著较高：分别为3.47 +/- 6.42（P <0.05）和62.91 +/- 21.96（P <0.05）;诊断为膀胱癌的血吸虫病患者的血药浓度分别为1.71 +/- 1.96（P <0.02）和44.94 +/- 7.31。在埃及对照组的两名志愿者的尿液中发现了游离亚硝酸盐（1.7和3.0微克/天），血吸虫病患者（5.18 +/- 9.11微克/天，P <0.02）和膀胱癌患者（1.75 +/- 2.81微克/天，P <0.05）的尿亚硝酸盐显著增加。硝酸盐浓度从对照组的139.3 +/- 82.2分别升高至血吸虫和膀胱癌组的143.6 +/- 136.3和175 +/- 190。这些结果表明，在体内的亚硝酸盐和挥发性N-亚硝基化合物发生在血吸虫病人的膀胱，这可能是一个病因学因素，在诱导血吸虫膀胱癌相关的。血吸虫感染
Saliva and 24-h urine samples were collected from male Schistosomiasis (bilharzia) patients with S. haematobium infection and possible concurrent S. mansoni infection without diagnosed bladder cancer (n = 27), bilharzia patients with diagnosed bladder cancer (n = 23) as well as a comparative control group (n = 27) of healthy Egyptian volunteers with no current bilharzia infection and/or bacterial urinary tract infections from the Nile Delta area of Egypt. Saliva samples were analysed for the presence of nitrate and nitrite; urine samples were analysed for the presence of nitrate, nitrite, volatile and non-volatile N-nitroso compounds. Bilharzia patients prior to, and after, diagnosed bladder cancer regularly excreted free nitrite as well as volatile nitrosamines (N-nitrosodimethylamine, N-nitrosodiethylamine, N-nitrosopiperidine and N-nitrosopyrrolidine) in addition to which elevated concentrations of non-volatile N-nitrosamino acids (N-nitrosoproline, N-nitrososarcosine, N-nitrosothiazolidine-4-carboxylic acid and its 2-methyl derivative) were also present. Total urinary excretion of volatile N-nitroso compounds (0.32 +/- 0.64 micrograms/day; mean +/- SD) and non-volatile N-nitroso compounds (31.20 +/- 22.07 micrograms/day) was observed in the Egyptian control group. Significantly higher concentrations were found in bilharzia patients: 3.47 +/- 6.42 (P less than 0.05) and 62.91 +/- 21.96 (P less than 0.05); as well as in bilharzia patients with diagnosed bladder cancer: 1.71 +/- 1.96 (P less than 0.02) and 44.94 +/- 7.31 respectively. Free nitrite was found in the urine of two volunteers in the Egyptian control group (1.7 and 3.0 micrograms/day), urinary nitrite was significantly increased in bilharzia patients (5.18 +/- 9.11 micrograms/day, P less than 0.02) and in bladder cancer patients (1.75 +/- 2.81 micrograms/day, P less than 0.05). Nitrate concentrations were elevated from 139.3 +/- 82.2 in the control group to 143.6 +/- 136.3 and 175 +/- 190 in the bilharzia and bladder cancer groups respectively. These results indicate that significant in vivo formation of nitrite and volatile N-nitroso compounds occurs in the urinary bladder of bilharzia patients and this may be an oetiological factor in the induction of bilharzial bladder cancer associated with S. haematobium infection.